Verus Capital Partners LLC Takes Position in Exagen Inc. (NASDAQ:XGN)

Verus Capital Partners LLC acquired a new position in Exagen Inc. (NASDAQ:XGN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 12,460 shares of the company’s stock, valued at approximately $39,000.

Several other institutional investors have also recently bought and sold shares of XGN. Renaissance Technologies LLC boosted its position in Exagen by 93.3% in the 2nd quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock valued at $172,000 after buying an additional 45,476 shares during the last quarter. Palumbo Wealth Management LLC lifted its stake in shares of Exagen by 14.5% during the third quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock valued at $236,000 after acquiring an additional 9,695 shares during the period. Finally, Creative Planning acquired a new position in shares of Exagen during the third quarter valued at $110,000. Institutional investors own 75.25% of the company’s stock.

Exagen Price Performance

Shares of XGN stock opened at $2.75 on Thursday. The firm’s 50 day moving average price is $2.84 and its two-hundred day moving average price is $2.37. The company has a debt-to-equity ratio of 1.13, a quick ratio of 4.32 and a current ratio of 4.32. Exagen Inc. has a 52-week low of $1.30 and a 52-week high of $3.71. The stock has a market cap of $47.82 million, a PE ratio of -2.88 and a beta of 1.35.

Exagen (NASDAQ:XGN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.02. The business had revenue of $12.51 million for the quarter, compared to analyst estimates of $13.55 million. Exagen had a negative return on equity of 84.26% and a negative net margin of 30.36%. During the same period last year, the company earned ($0.31) EPS. As a group, analysts forecast that Exagen Inc. will post -1.02 EPS for the current year.

Analyst Ratings Changes

Separately, William Blair reiterated an “outperform” rating on shares of Exagen in a research report on Wednesday.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).